top of page


Pelthos and Castle Creek agree biotechnology merger with up to $300 million in contingent milestone payments
Pelthos Therapeutics and Castle Creek Biosciences have agreed to merge, combining a dermatology portfolio with a fibroblast-based cell and gene therapy platform for serious skin diseases.

nuaxia
Nov 32 min read


Galderma agrees $1.5 billion acquisition of ZO Skin Health to expand dermatological skincare portfolio
Galderma has agreed to acquire ZO Skin Health for an enterprise value of $1.5 billion, expanding its physician-dispensed dermatological skincare portfolio.

nuaxia
Oct 152 min read


FDA approves Novartis Rhapsido as first treatment for symptomatic dermographism
Novartis has secured FDA approval for Rhapsido as the first treatment specifically approved for symptomatic dermographism in adults inadequately controlled by H1 antihistamines.

nuaxia
Oct 82 min read


FDA expands Olumiant approval to adolescents with severe alopecia areata
The expanded indication extends Lilly's JAK inhibitor to adolescents aged 12 years and older with severe alopecia areata.

nuaxia
Sep 281 min read


European Commission approves Icotyde for moderate-to-severe plaque psoriasis
The European Commission has authorised Icotyde for adults and adolescents with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

nuaxia
Sep 231 min read


FDA approves Ameluz photodynamic therapy for superficial basal cell carcinoma
The FDA has expanded the approved use of Ameluz with red-light photodynamic therapy to include treatment of superficial basal cell carcinoma in adults.

nuaxia
Sep 162 min read


US Dermatologist Compensation Reaches $497,509 in Doximity’s 2026 Report
Average annual compensation for US dermatologists reached $497,509 in Doximity’s 2026 Physician Compensation Report, providing an updated national benchmark for physicians working in dermatology.

nuaxia
Sep 43 min read


FDA approves RHA Redensity Eye as first hyaluronic acid filler specifically indicated for under-eye hollows
The approval provides clinicians with a dedicated injectable treatment for moderate to severe infraorbital hollowing in adults aged 22 years and older, expanding aesthetic treatment options for the under-eye region.

nuaxia
Aug 212 min read


LEO Pharma acquires worldwide rights to dersimelagon in deal worth up to $435 million
The agreement adds a late-stage oral therapy for rare genetic photodermatoses to LEO Pharma's dermatology pipeline while expanding its focus on rare skin diseases.

nuaxia
Aug 202 min read


British Columbia Dermatologist Billings Reach C$535,949, 7% Above Manitoba
New physician payment data show dermatologists generated higher median gross billings in British Columbia than in Manitoba.

nuaxia
Aug 183 min read


Medscape Dermatology Compensation Report 2026
Dermatology earnings flatten: positioning now defines outcomes, not progression

nuaxia
Jun 224 min read
bottom of page